J. Bostoen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
J. Bostoen has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Jo Lambert
Department of Dermatology Ghent University Hospital Ghent Belgium
3 shared publications B. Geusens
Department of Dermatology, Ghent University Hospital, Ghent, Belgium
1 shared publicationD. De Smedt
Department of Public Health, Ghent University Hospital, Ghent, Belgium
1 shared publicationH. Mielants
Department of Rheumatology, Ghent University Hospital, Ghent, Belgium
1 shared publicationJ. Boone
Centre of Sports Medicine, Ghent University Hospital, Ghent, Belgium
1 shared publicationJ. Bourgois
Centre of Sports Medicine, Ghent University Hospital, Ghent, Belgium
1 shared publication
Latest Publications
- 28 December 2012
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 28 (4) , 507-511
A cross‐sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis
Background Increasing epidemiological evidence suggests associations between psoriasis, psoriatic arthritis (PsA) and metabolic disease. Elucidating the complex relationship between these comorbidities may have important management implications.Objective The aim of this study was to examine the difference in prevalence of metabolic disease burden between patients with psoriasis who lack arthritic manifestations (PsO) and PsA patients.Methods We performed a cross‐sectional study in 123 patients with PsO and PsA. Metabolic syndrome was defined using the new criteria developed by the International Diabetes Foundation (IDF) in 2004. Therefore, clinical examination and standard survey were performed and fasting blood samples were collected.Results One hundred and four patients were analysed, of which 49 were PsO and 55 were PsA patients. We found that prevalence of the metabolic syndrome according to the IDF criteria was significantly higher in the PsO (44.9%) compared with the PsA group (25.5%) (P = 0.037). Looking closer at the individual components of the metabolic syndrome, this difference can mainly be attributed to the significantly higher prevalence of abdominal obesity in PsO (83.7%) vs. PsA (65.5%) (P = 0.034). For other individual components of the metabolic syndrome such as triglycerides, high‐density lipoproteins, hypertension and plasma glucose, we could not show statistically significant differences between the groups.Conclusion Metabolic syndrome is more prevalent in patients with PsO than in PsA patients, mainly determined by the higher prevalence of abdominal obesity in PsO compared with PsA group.
- 28 December 2012
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 28 (4) , 507-511
A cross‐sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis
Background Increasing epidemiological evidence suggests associations between psoriasis, psoriatic arthritis (PsA) and metabolic disease. Elucidating the complex relationship between these comorbidities may have important management implications.Objective The aim of this study was to examine the difference in prevalence of metabolic disease burden between patients with psoriasis who lack arthritic manifestations (PsO) and PsA patients.Methods We performed a cross‐sectional study in 123 patients with PsO and PsA. Metabolic syndrome was defined using the new criteria developed by the International Diabetes Foundation (IDF) in 2004. Therefore, clinical examination and standard survey were performed and fasting blood samples were collected.Results One hundred and four patients were analysed, of which 49 were PsO and 55 were PsA patients. We found that prevalence of the metabolic syndrome according to the IDF criteria was significantly higher in the PsO (44.9%) compared with the PsA group (25.5%) (P = 0.037). Looking closer at the individual components of the metabolic syndrome, this difference can mainly be attributed to the significantly higher prevalence of abdominal obesity in PsO (83.7%) vs. PsA (65.5%) (P = 0.034). For other individual components of the metabolic syndrome such as triglycerides, high‐density lipoproteins, hypertension and plasma glucose, we could not show statistically significant differences between the groups.Conclusion Metabolic syndrome is more prevalent in patients with PsO than in PsA patients, mainly determined by the higher prevalence of abdominal obesity in PsO compared with PsA group.
- 18 June 2012
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 167 (5) , 1025-1031
An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial
Background Patient education in addition to standard treatment, with the aim of affecting care through courses, is a relatively new concept in dermatology. Here we introduce a randomized controlled trial (RCT) regarding a previously described 12‐week educational programme for chronic skin diseases. Objectives The primary objective of the RCT was to measure the effect of an educational programme on disease severity and quality of life in patients with psoriasis or atopic dermatitis. Methods We recruited 50 patients from Ghent University Hospital. Patients with diagnosed psoriasis or atopic dermatitis were randomized (1 : 1) to the intervention or control group. The clinical outcome was measured by two blinded observers using the Psoriasis Area and Severity Index (PASI), Scoring Atopic Dermatitis or the Eczema Area and Severity Index. Quality of life was measured by dermatology‐specific quality‐of‐life questionnaires. There was a follow‐up period of 9 months. Results We found that disease severity and quality of life improved significantly for patients with psoriasis (n = 29) but not for patients with atopic dermatitis (n = 21) at 3 months. Patients in the intervention group showed a significant reduction in mean PASI (P = 0·036), mean Dermatology Life Quality Index (P = 0·019) and mean Psoriasis Disability Index (P = 0·015), compared with the control group at 3 months. This improvement continued for at least 6 months, i.e. 3 months after the intervention, but was lost at follow‐up after 9 months. Conclusions Evaluating this form of educational programme, by means of a single‐centre RCT, indicates its added value in the longer term management of psoriasis.
- 18 June 2012
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 167 (5) , 1025-1031
An educational programme for patients with psoriasis and atopic dermatitis: a prospective randomized controlled trial
Background Patient education in addition to standard treatment, with the aim of affecting care through courses, is a relatively new concept in dermatology. Here we introduce a randomized controlled trial (RCT) regarding a previously described 12‐week educational programme for chronic skin diseases. Objectives The primary objective of the RCT was to measure the effect of an educational programme on disease severity and quality of life in patients with psoriasis or atopic dermatitis. Methods We recruited 50 patients from Ghent University Hospital. Patients with diagnosed psoriasis or atopic dermatitis were randomized (1 : 1) to the intervention or control group. The clinical outcome was measured by two blinded observers using the Psoriasis Area and Severity Index (PASI), Scoring Atopic Dermatitis or the Eczema Area and Severity Index. Quality of life was measured by dermatology‐specific quality‐of‐life questionnaires. There was a follow‐up period of 9 months. Results We found that disease severity and quality of life improved significantly for patients with psoriasis (n = 29) but not for patients with atopic dermatitis (n = 21) at 3 months. Patients in the intervention group showed a significant reduction in mean PASI (P = 0·036), mean Dermatology Life Quality Index (P = 0·019) and mean Psoriasis Disability Index (P = 0·015), compared with the control group at 3 months. This improvement continued for at least 6 months, i.e. 3 months after the intervention, but was lost at follow‐up after 9 months. Conclusions Evaluating this form of educational programme, by means of a single‐centre RCT, indicates its added value in the longer term management of psoriasis.
- 15 September 2010
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 303 (1) , 57-63
A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results
Chronic inflammatory skin disorders have a major impact on the patients’ health related quality of life. Preliminary studies to date have suggested that additional educational and psychological training programmes may be effective in the management of chronic skin diseases, although more rigid methodology is needed. Our purpose was to investigate the effect on quality of life of a novel multidisciplinary educational programme for patients, 18 years or older, with chronic skin diseases. The 12-week intervention encompasses cognitive education on skin and general health issues, and stress-reducing techniques. Quality of life questionnaires were used to assess the participants at baseline and at the end of the program. These comprehend Dermatology Life Quality Index (DLQI), Skindex-29, Psoriasis Disability Index (PDI) and Quality of Life Index for Atopic Dermatitis (QoLIAD). Fifty-five patients participated in six programmes since 2006. Forty-three patients completed the programme. Overall, compared to baseline, DLQI (n = 39) improved by 5.64 points (p < 0.001; SD ±6.09), Skindex-29 (n = 27) by 19.67 points (p < 0.001; SD ±17.37), PDI (n = 9) improved by 7.44 points (p = 0.019; SD ±7.60) and QoLIAD (n = 13) improved by 4.39 points (p = 0.036; SD ±6.69) by the end of the intervention. Preliminary results show that the quality of life of the patients with chronic skin diseases improved significantly after participation to the programme. These positive initial results are stimulating to set up a prospective controlled randomised trial investigating the impact on quality of life, the clinical efficacy and the cost-effectiveness of this educational intervention programme.
- 15 September 2010
- Published by Springer Nature in Archives of Dermatological Research
- Vol. 303 (1) , 57-63
A novel multidisciplinary educational programme for patients with chronic skin diseases: Ghent pilot project and first results
Chronic inflammatory skin disorders have a major impact on the patients’ health related quality of life. Preliminary studies to date have suggested that additional educational and psychological training programmes may be effective in the management of chronic skin diseases, although more rigid methodology is needed. Our purpose was to investigate the effect on quality of life of a novel multidisciplinary educational programme for patients, 18 years or older, with chronic skin diseases. The 12-week intervention encompasses cognitive education on skin and general health issues, and stress-reducing techniques. Quality of life questionnaires were used to assess the participants at baseline and at the end of the program. These comprehend Dermatology Life Quality Index (DLQI), Skindex-29, Psoriasis Disability Index (PDI) and Quality of Life Index for Atopic Dermatitis (QoLIAD). Fifty-five patients participated in six programmes since 2006. Forty-three patients completed the programme. Overall, compared to baseline, DLQI (n = 39) improved by 5.64 points (p < 0.001; SD ±6.09), Skindex-29 (n = 27) by 19.67 points (p < 0.001; SD ±17.37), PDI (n = 9) improved by 7.44 points (p = 0.019; SD ±7.60) and QoLIAD (n = 13) improved by 4.39 points (p = 0.036; SD ±6.69) by the end of the intervention. Preliminary results show that the quality of life of the patients with chronic skin diseases improved significantly after participation to the programme. These positive initial results are stimulating to set up a prospective controlled randomised trial investigating the impact on quality of life, the clinical efficacy and the cost-effectiveness of this educational intervention programme.